Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer

British Journal of Cancer

Volumn 74, Issue 2, 1996, Pages 300-308

  Howell, A ^a   DeFriend, D J ^b   Robertson, J F R ^c   Blamey, R W ^c   Anderson, L ^a   Anderson, E ^d   Sutcliffe, F A ^e   Walton, P ^e  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^d CHRISTIE HOSPITAL   (United Kingdom)

^e ASTRAZENECA   (United Kingdom)

Author keywords

Advanced breast cancer; ICI 182780

Indexed keywords

FOLLITROPIN; FULVESTRANT; LIPID; LUTEINIZING HORMONE; PROLACTIN; SEX HORMONE BINDING GLOBULIN; TAMOXIFEN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLITROPIN BLOOD LEVEL; HOT FLUSH; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; INJECTION PAIN; INTRAMUSCULAR DRUG ADMINISTRATION; LIPID BLOOD LEVEL; LUTEINIZING HORMONE BLOOD LEVEL; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SWEAT; VAGINA DISCHARGE;

EID: 0030016280     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.357     Document Type: Article

References (49)

1. BERTELLI G, PRONZATO P, AMOROSO D, CUSIMANO MP, CONTE PF, MONTAGNA G, BERTOLONI S AND ROSSO R. (1988). Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels. Breast Cancer Res. Treat., 12, 307-310.
2. BRUNNER N, BOYSON B, KILGAARD JF, JIRUS S AND CLARKE R. (1993a). Resistance to 4OH-tamoxifen does not confer resistance to the steroidal antioestrogen ICI 182780, while acquired resistance to ICI 182780 results in cross-resistance to 4OH-tamoxifen. (abstract 19). Breast Cancer Res. Treat., 27, 135.
3. BRUNNER N, FRANDSEN TL, HOLST-HANSEN C, BEI M, THOMPSON EW, WAKELING AE, LIPPMAN ME AND CLARKE R. (1993b). MCF-7/LCC2: a 4-hydroxy-tamoxifen resistant human breast cancer variant which retains sensitivity to the steroidal antioestrogen ICI 182780. Cancer Res., 53, 3229-3232.
4. CLARKE RB, LAIDLAW IJ, JONES LJ, HOWELL A AND ANDERSON E. (1993). Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. Br. J. Cancer, 67, 606-611.
5. COHEN I, ROSEN DJ, TEPPER R, CORDOBA M, SHAPIRA Y, ALTARAS MM, YIGAEL D AND BEYTH Y. (1994). Ultrasonographic evaluation of the endometrium and correlation with endometrial sampling in postmenopausal patients treated with tamoxifen. J. Ultrasound Med., 12, 275-280.
6. COLE MP, JONES CTA AND TODD IDJ. (1971). A new antioestrogenic agent in late breast cancer. An early clinical appraisal of ICI 46,474. Br. J. Cancer, 25, 270-275.
7. COOPMAN P, GARCIA M, BRUNNER N, DEROCQ D, CLARKE R AND ROCHEFORT H. (1994). Anti-proliferative and antioestrogenic effects of ICI 164,384 and ICI 182,780 in 4-OH-Tamoxifen resistant human breast cancer cells. Int. J. Cancer, 56, 295-300.
8. CRUZ JM, MUSS HB, BROCKSCHMIDT JK AND EVANS GW. (1990). Weight changes in women with metastatic breast cancer treated with megestrol acetate: a comparison of standard versus high-dose therapy. Semin. Oncol., 17, 63-67.
9. DAUVOIS S, DANIELIAN PS, WHITE R AND PARKER MG. (1992). Antioestrogen ICI 164384 reduced cellular estrogen receptor content by increasing its turnover. Proc. Natl. Acad. Sci. USA, 89, 4037-4041.
10. DEFRIEND DJ, ANDERSON E, BELL J, WILKS DP, WEST CML AND HOWELL A. (1994a). Effects of 4-hydroxytamoxifen and a pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro. Br. J. Cancer, 70, 2043-211.
11. DEFRIEND DJ, HOWELL A, NICHOLSON RI, ANDERSON E, DOWSETT M, MANSEL RE, BLAMEY RW, BUNDRED NJ, ROBERTSON JF, SAUNDERS C, BAUM M, WALTON P, SUTCLIFFE F AND WAKELING AE. (1994b). Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res., 54, 408-414.
12. DUKES M, WATERTON JC, WAKELING AE. (1993). Antiuterotrophic effects of the pure antioestrogen ICI 182,780 in adult female monkeys (Macaca-nemestrina) - Quantitative magnetic resonance imaging. J. Endocr., 138, 203.
13. FAWELL SE, WHITE R, HOARE S, SYDENHAM M, PAGE M AND PARKER MG. (1990). Inhibition of oestrogen receptor-DNA binding by the 'pure' antioestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc. Natl Acad. Sci. USA, 87, 6883-6887.
14. FORNANDER T, RUTQVIST LE AND CEDERMARK B. (1989). Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet, 1, 117-120.
15. FRIEDEWALD WT, LEVI RI AND FREDRICKSON DS. (1972). Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem., 18, 499-502.
16. GOTTARDIS MM, JIANG SY, YENG MH, JORDAN VC. (1989). Inhibition of tamoxifen-stimulated growth of an MCF-7 variant in athymic mice by novel steroidal antioestrogens. Cancer Res., 49, 4090-4093.
17. HAYWARD JL, CARBONE PP, HEUSON JC, KUMASKA S, SEGALOFF A AND RUBENS RD. (1977). Assessment of response to therapy in advanced breast cancer. Eur. J. Cancer, 13, 11-33.
18. HOWELL A, MACKINTOSH J, JONES M, REDFORD J, WAGSTAFF J AND SELLWOOD RA. (1988). The definition of the 'No Change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur. J. Cancer Clin. Oncol., 24, 156-157.
19. HOWELL A, DODWELL D, LAIDLAW I, ANDERSON H AND ANDERSON E. (1990). Tamoxifen as an agonist for metastatic breast cancer. In Endocrine Therapy of Breast Cancer IV, Goldhirsch A (ed.) pp. 49-58. Springer: Berlin.
20. HOWELL A, DODWELL D, ANDERSON H AND REDFORD J. (1992). Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. Ann. Oncol., 3, 611-617.
21. HOWELL A, DE FRIEND D, ROBERTSON J, BLAMEY R AND WALTON P. (1995). Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet, 345, 29-30.
22. IGNAR-TROWBRIDGE DM, NELSON KG, BIDWELL MC, CURTIS SW, WASHBURN TF, MC LACHLAN JA AND KORACH KS. (1992). Coupling of dual signalling pathways: epidermal growth factor action involves the oestrogen receptor. Proc. Natl Acad. Sci. USA, 89, 4658-4662.
23. LOVE R, NEWCOMB P AND WIEBE D. (1990). Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J. Natl Cancer Inst., 82, 1327-1332.
24. LYKKESFELDT AE AND SORENSEN EK. (1992). Effect of oestrogen and anti-oestrogen on cell-proliferation and synthesis of secreted proteins in the human breast cancer cell line MCF-7 and a tamoxifen resistant variant subline, AL-1. Acta Oncol., 31, 131-138.
25. 1. Cancer Res, 54, 1587-1595.
26. NICHOLSON RI, FRANCIS AB, MCCLELLAND RA, MANNING DL AND GEE JMW. (1994). Pure anti-oestrogens (ICI 164384 and ICI 182780) and breast cancer: is the attainment of complete oestrogen withdrawal worthwhile? Endocrine Related Cancer, 1, 5-17.
27. OSBORNE CK, CORONADO E AND ALLRED CD. (1991). Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J. Natl Cancer Inst., 83, 1477-1482.
28. PATTERSON JS, EDWARDS DG AND BATTERSBY LA. (1981). A review of the international clinical experience with tamoxifen. Jpn J. Cancer Clin., Supplement (November), 157-183.
29. PAVLIK EJ, NELSON K AND SRINIVASAN S. (1992). Resistance to tamoxifen with persisting sensitivity to estrogen: possible mediation by excessive antiestrogen binding site activity. Cancer Res., 52, 4106-4112.
30. POWER RF, MANI SK, CODINA J, CONNEELLY OM AND O'MALLEY BW. (1991). Dopaminergic and ligand-independent activation of steroid hormone receptors. Science, 244, 1636-1639.
31. REDDY KB, MANGOLD GL, TANDON AK, YONEDA T, MUNDY GR, ZILBERSTEIN A AND OSBORNE CK. (1992). Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor. Cancer Res., 52, 3636-3641.
32. ROBERTSTON JFR, WILLIAMS MR, TODD J, NICHOLSON RI, MORGAN DAL AND BLAMEY RW. (1989). Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy. Eur. J. Cancer. Clin. Oncol., 25, 469-475.
33. ROBERTSON JFR, ELLIS IO, NICHOLSON RI, ROBINS A, BELL J AND BLAMEY RW. (1991). Cellular effects of tamoxifen in primary breast cancer. Breast Cancer Res. Treat., 20, 117-123.
34. SAKAI F, CHEIX F, CLAVEL M, COLON J, MAYER M, PANNATA F AND SAEZ S. (1978). Increases in steroid binding globulins induced by tamoxifen in patients with carcinoma of the breast. J. Endocrinology, 76, 219-226.
35. SIMON W, ALBRECHT M AND TRAMS G. (1984). In-vitro growth promotion of human mammary carcinoma cells by steroidal hormones, tamoxifen and prolactin. J. Natl Cancer Inst., 73, 313-321.
36. STEWART AJ, WESTLEY BR, MAY FEB AND WESTLEY BR. (1990). Modulation of proliferative response of breast cancer cells to growth factors by oestrogen. Br. J. Cancer, 66, 640-648.
37. THOMAS EJ, THOMAS NM, WALTON PL AND DOWSETT M. (1993). The effects of ICI 182,780, a pure antioestrogen on reproductive endocrinology in normal pre-menopausal women. J. Endocrinol., 137S, 183.
38. TURKEN S, SIRIS E AND SELDON. (1989). Effects of tamoxifen on spinal bone density in women with breast cancer. J. Natl Cancer Inst., 81, 1086-1088.
39. VOGEL CL, SHEMANO I, SCHOENFELDER J, GAMS RA AND GREEN MR. (1993). Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer. J. Clin. Oncol., 11, 345-350.
40. WAKELING AE. (1993). The future of new pure antiestrogens in clinical breast cancer. Breast Cancer Res. Treat., 25, 1-9.
41. WAKELING AE AND BOWLER J. (1987). Steroidal pure anti-oestrogens. J. Endocrinol., 112, R7-R10.
42. WAKELING AE AND BOWLER J. (1988). Novel anti-oestrogens without partial agonist activity. J. Steroid Biochem., 31, 645-653.
43. WAKELING AE, NEWBOULT E AND PETERS SW. (1989). Effects of anti-oestrogens on the proliferation of MCF-7 human breast cancer cells. J. Mol. Endocrinol., 2, 225-234.
44. WAKELING AE, DUKES M AND BOWLER J. (1991). A potent specific pure antioestrogen with clinical potential. Cancer Res., 51, 3867-3873.
45. WAKELING AE, BARKER AJ, DAVIES DH, BROWN DS, GREEN LR, CARTLIDGE SA AND WOODBURN JR. (1994). Inhibition of EGF-receptor tyrosine kinase activity by 4-aniloquinazolines. (abstract 6.6). Br. J. Cancer, 69 (suppl. 21), 18.
46. WESTLEY BR AND MAY FEB. (1991). IGF's and control of cell proliferation in breast and other cancers. Rev. Endocrine Rel. Cancer, 39, 29-34.
47. WILLEMSE PHB, VAN DER PLOEG E, SLEIJFER D, TJABBES T AND VAN VEELEN HA. (1990). A randomized comparison of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in patients with advanced breast cancer. Eur. J. Cancer, 26, 337-343.
48. WILLIS KJ, LONDON DR, WARD HWC, BUTT WR, LYNCH SS AND RUDD BT. (1977). Recurrent breast cancer treated with the antioestrogen tamoxifen: correlation between hormonal changes and clinical course. Br. Med. J., 1, 425-428.
49. WOLF DM, LANGAN-FAHEY, PARKER CJ, MCGAGUE R AND CRAIG JORDAN V. (1993). Investigation of the mechanism of tamoxifen-stimulated breast tumour growth with nonisomerizable analogues of tamoxifen and metabolites. J. Natl Cancer Inst., 85, 806-812.